<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887156</url>
  </required_header>
  <id_info>
    <org_study_id>K180304J</org_study_id>
    <nct_id>NCT03887156</nct_id>
  </id_info>
  <brief_title>Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft</brief_title>
  <acronym>Predictor2</acronym>
  <official_title>Evaluation of a Donor Testing Kit for the Prediction of Acute GVHD in Patient Receiving a Peripheral Blood Stem Cells Allograft- Predictor 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SATT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SNC Graft Versus Host Disease</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imagine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AXONAL-BIOSTATEM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CERBA laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to validate an in vitro diagnosis medical device to predict grade II to IV aGVHD
      after a cell graft
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute Graft Versus Host Disease (aGVHD) is the most frequent complication in allogeneic
      Hematopoietic Stem Cell Transplantation (allo-HSCT). It affects up to 50% patients, among
      whom 15% to 25% develop severe forms, often lethal, yet impossible to predict even for donors
      with a Human Leukocyte Antigene (HLA) 10/10 compatibility. Global Overall Survival (OS) after
      transplantation is 40% to 60% only due to post transplant severe complications. There is a
      major medical need for a technology that would predict the risk of aGVHD and would allow the
      selection of a favourable donor among multiple Human Leukocyte Antigene (HLA)10/10 compatible
      donors.

      MT. Rubio and M. Bouillié at Pr Olivier Hermine's lab previously reported that enhanced early
      post-transplant invariant Natural Killer T (iNKT) cells reconstitution from donor cells was
      correlated to reduced risk of aGVHD, without impairment of the Graft Versus Leukemia (GVL)
      effect. They subsequently demonstrated that the expansion of donors CD4neg invariant Natural
      Killer T (iNKT) cells subpopulation was predictive of a reduced risk of aGVHD, and developed
      a method for predicting this risk based on the expansion factor of CD4neg invariant Natural
      Killer T (iNKT) cells in the peripheral blood stem cell (PBSC) graft. This invariant Natural
      Killer T (iNKT) cells functional test reaches its optimal predictive capacity with 94%
      sensitivity and 100% specificity in allo-HSCT performed with Human Leukocyte Antigene (HLA)
      10/10 matched peripheral blood stem cell (PBSC) grafts for non-progressive hematological
      malignant diseases, in complete response, which represent the majority of the indications of
      allogeneic HSCT. Similar predictive value was also observed when the test was performed from
      donor's peripheral blood before G-CSF mobilization. It was not associated with an increased
      risk of relapse. This test could therefore allow to easily selecting the best donor if
      different siblings or unrelated donors are available before PBSC allo-HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of aGVHD of grade II to IV observed for the recipients</measure>
    <time_frame>3 month after allograft performance</time_frame>
    <description>To predict the risk of acute GVHD. Number of aGVHD of grade II to IV observed for the recipients in the 3 months after the graft and results of the Predictor test, before graft, on their own donor's blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of medico-economic aspect of the Predictor test Total estimated cost of the aGVHD treatment</measure>
    <time_frame>3 month after allograft performance.</time_frame>
    <description>Number of hospitalization or medical consultation, exams, concomitant treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the medico-economic aspect of the Predictor test Total estimated cost of the aGVHD treatment</measure>
    <time_frame>3 month after allograft performance.</time_frame>
    <description>Number of medical consultations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the medico-economic aspect of the Predictor test Total estimated cost of the aGVHD treatment</measure>
    <time_frame>3 month after allograft performance.</time_frame>
    <description>Number of exams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the medico-economic aspect of the Predictor test Total estimated cost of the aGVHD treatment</measure>
    <time_frame>3 month after allograft performance.</time_frame>
    <description>Number of concomitant treatments</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">227</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Lymphoma in Remission</condition>
  <condition>Non-progressive Myeloproliferative Syndrome</condition>
  <condition>Myelodysplasia With Stable Blasts is Cell Number and &lt; 10% of Blastocysts</condition>
  <condition>Acute Leukemia Biphenotypic in Remission</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test</intervention_name>
    <description>Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PATIENT :

               -  Age between 18 and 65 years ( included )

               -  Being candidate to a graft of peripheral hematopoietic stem cells , according the
                  following criteria :

          -  HLA compatibility 10 / 10 with the selected donor

          -  Malignant haematological disorder as described below :

               -  Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia ( ALL) in 1st or 2d
                  complete remission

               -  Aggressive lymphoma in complete remission

               -  Non - progressive myeloproliferative syndrome ,

               -  Myelodysplasia with stable blasts is cell number and &lt; 10 % of blastocysts,

               -  Acute leukemia biphenotypic in 1st or 2d complete remission

          -  Sequential graft conditioning, myeloablative or with a reduced intensity, both may
             include ATG

          -  Classical scheme for immunosuppression decrease ( from day 90 to day 180 ) • Not being
             opposed to medical data collection DONOR

          -  Adult ( ≥ 18 year old) up to the maximum authorized by each National Transplantation
             Authority

          -  Being a patient's sibling or registered in the Bone Marrow Donors Worldwide registry
             or a national registry

          -  Being candidate to a Peripheral Blood Stem Cells donation with a Human Leucocyt
             Antigen (HLA) 10 / 10 compatibility with the recipient ,

          -  Signed and dated informed consent ( in accordance with local regulation of the country
             in which the observation is performed )

        Exclusion Criteria:

          -  Participating in a clinical trial, if interventional on the prophylaxis treatment (
             not on the prophylaxis ) of GVHD, in the 30 days prior to the inclusion and during the
             Predictor 2 study ,

          -  Being placed under legal supervision ,

          -  Presenting any impossibility to fulfil the study requirements, due to geographical,
             social or physical reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hermine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of adult hematology department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shohreh Azimi</last_name>
    <phone>+33 (0)1 44 84 17 79</phone>
    <email>shohreh.azimi@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bénédicte SAMEY</last_name>
    <phone>+33 1 56 38 21 58</phone>
    <email>bsamey@axonal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen Normandie</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Hestaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuyten</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Pr Moreau</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>: Groupe hospitalier de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitiè-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Rubio MT, Bouillié M, Bouazza N, Coman T, Trebeden-Nègre H, Gomez A, Suarez F, Sibon D, Brignier A, Paubelle E, Nguyen-Khoc S, Cavazzana M, Lantz O, Mohty M, Urien S, Hermine O. Pre-transplant donor CD4(-) invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease. Leukemia. 2017 Apr;31(4):903-912. doi: 10.1038/leu.2016.281. Epub 2016 Oct 14.</citation>
    <PMID>27740636</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

